Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06522386 · ClinicalTrials.gov registry record · Phase 2
GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma
A Phase 2 study of Mantle Cell Lymphoma, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 2
- Study locations
NCT06522386 is a Phase 2 study of Mantle Cell Lymphoma that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 40 participants, below the 104-participant average among 102 other Mantle Cell Lymphoma trials with a reported enrollment target (62% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT06522386, a Phase 2 study of Mantle Cell Lymphoma, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 2
- Study locations
Study Summary
Primary Objectives: To estimate the percent of participants who achieve a best response of complete response by the end of the PRV combination therapy in the induction therapy phase in patients with previously untreated MCL.
Conditions Studied
Interventions
- DRUG Venetoclax
- DRUG Rituximab
- DRUG Pirtobrutinib
Study Locations (2)
Minnesota
- Mayo Clinic in Rochester - Rochester
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-01-30 |
| Est. Completion | 2029-02-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06522386
The ClinicalTrials.gov registry entry for NCT06522386 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 104-participant average among 102 other Mantle Cell Lymphoma trials with a reported enrollment target (62% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Mantle Cell Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Venetoclax is the first listed.
NCT06522386 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Minnesota, Texas.
Frequently Asked Questions
What is clinical trial NCT06522386 about?
NCT06522386 is a clinical study titled "GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma". Primary Objectives: To estimate the percent of participants who achieve a best response of complete response by the end of the PRV combination therapy in the induction therapy phase in patients with previously untreated MCL.
What is the current status of trial NCT06522386?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2025-01-30. Estimated completion is 2029-02-28.
What conditions does trial NCT06522386 study?
This clinical trial studies the following conditions: Mantle Cell Lymphoma.
What interventions are being tested in trial NCT06522386?
The interventions under investigation include: Venetoclax (DRUG), Rituximab (DRUG), Pirtobrutinib (DRUG).
Who is sponsoring clinical trial NCT06522386?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06522386 being conducted?
This trial has 2 study locations across Minnesota, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mantle Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma
RECRUITING · Phase 2
-
Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL
RECRUITING · Phase 2
-
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
RECRUITING · Phase 2
-
Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
RECRUITING · Phase 2
-
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
RECRUITING · Phase 2
-
Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.